Ukraine, Egypt explore preferential trade deal: Zelenskyy    Egypt, Russia's Rosatom review grid readiness for El-Dabaa nuclear plant    Mastercard Unveils AI-Powered Card Fraud Prevention Service in EEMEA Region, Starting from Egypt    Global tour for Korean 'K-Comics' launches in Cairo with 'Hellbound' exhibition    China's factory output expands in June '25    Egyptian pound climbs against dollar at Wednesday's close    New accords on trade, security strengthen Egypt-Oman Relations    Egypt launches public-private partnership to curb c-sections, improve maternal, child health    Gaza under Israeli siege as death toll mounts, famine looms    EMRA, Elsewedy sign partnership to explore, develop phosphate reserves in Sebaiya    Philip Morris Misr announces new price list effective 1 July    Egypt Post discusses enhanced cooperation with Ivorian counterpart    Egypt's Environment Minister calls for stronger action on desertification, climate resilience in Africa    Egypt in diplomatic push for Gaza truce, Iran-Israel de-escalation    Egypt teams up with private sector to boost university rankings    Egypt reveals heritage e-training portal    Three ancient rock-cut tombs discovered in Aswan    Egypt condemns deadly terrorist attack in Niger    Egypt, Tunisia discuss boosting healthcare cooperation        Egypt's EHA, Schneider Electric sign MoU on sustainable infrastructure    Sisi launches new support initiative for families of war, terrorism victims    Grand Egyptian Museum opening delayed to Q4    Egypt expands e-ticketing to 110 heritage sites, adds self-service kiosks at Saqqara    Egypt's Irrigation Minister urges scientific cooperation to tackle water scarcity    Egypt discovers three New Kingdom tombs in Luxor's Dra' Abu El-Naga    Palm Hills Squash Open debuts with 48 international stars, $250,000 prize pool    Egypt's Democratic Generation Party Evaluates 84 Candidates Ahead of Parliamentary Vote    On Sport to broadcast Pan Arab Golf Championship for Juniors and Ladies in Egypt    Golf Festival in Cairo to mark Arab Golf Federation's 50th anniversary    Germany among EU's priciest labour markets – official data    Cabinet approves establishment of national medical tourism council to boost healthcare sector    Egypt's PM follows up on Julius Nyerere dam project in Tanzania    Egypt's FM inspects Julius Nyerere Dam project in Tanzania    Paris Olympic gold '24 medals hit record value    A minute of silence for Egyptian sports    Russia says it's in sync with US, China, Pakistan on Taliban    It's a bit frustrating to draw at home: Real Madrid keeper after Villarreal game    Shoukry reviews with Guterres Egypt's efforts to achieve SDGs, promote human rights    Sudan says countries must cooperate on vaccines    Johnson & Johnson: Second shot boosts antibodies and protection against COVID-19    Egypt to tax bloggers, YouTubers    Egypt's FM asserts importance of stability in Libya, holding elections as scheduled    We mustn't lose touch: Muller after Bayern win in Bundesliga    Egypt records 36 new deaths from Covid-19, highest since mid June    Egypt sells $3 bln US-dollar dominated eurobonds    Gamal Hanafy's ceramic exhibition at Gezira Arts Centre is a must go    Italian Institute Director Davide Scalmani presents activities of the Cairo Institute for ITALIANA.IT platform    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.



Britain secures 60 mln doses of Sanofi/GSK coronavirus vaccine
Published in Ahram Online on 29 - 07 - 2020

Britain has signed a deal for up to 60 million doses of a potential coronavirus vaccine being developed by Sanofi and GlaxoSmithKline (GSK), it said on Wednesday, its latest such arrangement as the race to tame the pandemic heats up.
With its four deals so far, Britain has struck more coronavirus vaccine supply agreements than any other country, securing 250 million doses for a population of 66 million.
But with no vaccine yet proven to work, a range of potential suppliers is seen as giving the best chance of success.
"The fact remains that there are no guarantees," said business minister Alok Sharma.
"It is important that we secure early access to a diverse range of promising vaccine candidates ... to increase our chances of finding one that works."
Sanofi and GSK confirmed in a statement that regulatory approval for their vaccine could be achieved by the first half of 2021 if clinical data was positive.
It is Sanofi and GSK's first deal to supply their experimental coronavirus vaccine to a country.
Financial terms were not disclosed.
Asked about the price, GSK CEO Emma Walmsley said only that GSK did not expect to profit from the product during the pandemic and any short-term earnings would be partly be reinvested into pandemic preparedness and donated to developing countries.
With more than 20 vaccines in human trials, the move could stir concerns that rich countries, including the United States and those in Europe, are scooping doses in advance, potentially to the detriment of poorer nations.
Last week, Britain struck deals for 30 million doses of an experimental BioNtech/Pfizer vaccine, and a deal in principle for 60 million doses of Valneva's potential shot, which followed a previously announced deal for 100 million doses of an experimental Oxford/AstraZeneca vaccine.
The EU and United States have secured 400 million and 300 million doses of the Oxford/AstraZeneca shot respectively, while the U.S. government has also agreed to buy 100 million doses of the Pfizer/BioNtech vaccine, with an option for 500 million more.
The Sanofi/GSK vaccine combines Sanofi's S-protein COVID-19 antigen and GSK's pandemic adjuvant technology, and the first clinical trials are expected in September.
Adjuvants are efficacy boosters that play a vital role in many traditional vaccines. Sanofi and GSK's vaccine uses a different approach from either the Oxford/AstraZeneca or Pfizer/BioNtech vaccines.
Sanofi and GSK said talks to supply their vaccine to the EU, Italy and France were ongoing.
The two firms hope to clinch a deal soon to provide 300 million doses to the EU, though two sources told Reuters that negotiations had stalled.
Britain decided against joining the EU's vaccine purchase scheme in order to strike its own deals.


Clic here to read the story from its source.